Intralesional Steroids in the Treatment of Alopecia Areata
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the frequency of response to treatment with 3 concentrations of
IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side
effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months,
nonresponders or partial responders may be treated for 6 months with open label triamcinolone
at the dose deemed appropriate by the investigator.
The investigators will also perform skin biopsies of the scalp and draw blood at selected
time points in order to examine the immunohistochemical/pathological response in scalp hair
follicles and the systemic circulation to treatment with IL TAC for alopecia areata.
Phase:
Phase 4
Details
Lead Sponsor:
Columbia University
Collaborators:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute